Receive Email Updates
This blog, Patents4Life, does not contain legal advice and is for informational purposes only. Its publication does not create an attorney-client relationship nor is it a solicitation for business. This is the personal blog of Warren Woessner and does not reflect the views of Schwegman Lundberg & Woessner, or any of its attorneys or staff. To the best of his ability, the Author provides current and accurate information at the time of each post, however, readers should check for current information and accuracy.
Category Archives: Int’l Practice and Policy
This newsletter (attached below) from a leading Indian firm, contains a good review of the perils of the working requirement in India. It also provides a good summary of three recent decisions holding pharma patents invalid for obviousness. What is striking is … Continue reading
Can everything old be made new again? Lots has been written about the Indian Supreme Court rejecting a patent application claiming a crystal modification of imatinib mesylate (Gleevec), which is used to treat CML. Novartis’ attempt to “evergreen” Gleevec with … Continue reading
As reported in Director Kappos’ blog, progress is being made in harmonizing the patent filing process in the IP5 countries. This may be as big an advance in patent law as the EPO – including our hope for a single … Continue reading